Abstract: Activated fibroblast growth factor receptor 4 (FGFR4) initiates STAT3, MAPK and PI3K/AKT signaling cascades, regulates the proliferation, differentiation and migration of cells. The FGFR4 signaling aberrations, such as mutation, overexpression or ligand overexpression, play crucial roles in the genesis and development of various tumor cells. It indicates that FGFR4 is a potential therapy target. Blocking FGFR4 signaling pathway is an effective method for treating tumors with FGFR4 signaling aberrations, which containing small molecule kinase inhibitor, monoclonal antibody, ligand capture protein and short RNA oligonucleotide adapter (shRNA). In this paper, we reviewed the abnormal signaling of FGFR4 in tumor and the research progress of anti-tumor drug.